Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis - Wikidata - wikimedia - TriplyDB

Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis

Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis

http://www.wikidata.org/entity/Q35555882

about

Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis--cross-sectional study and literature review Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis.Serum Biomarkers for Discrimination between Hepatitis C-Related Arthropathy and Early Rheumatoid Arthritis.Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance Anti-cyclic citrullinated peptide antibodies in ulcerative colitis, and its relation with disease activity.Missing links in high quality diagnostics of inflammatory systemic rheumatic diseases: It is all about the patient!Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics.Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not?Ectopic lymphoid neogenesis in psoriatic arthritis.Changes in proliferation kinetics of T cells: a new predictive cellular biomarkers for early rheumatoid arthritis?Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis.Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis.The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases.Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.Clinical significance of anti-cyclic citrullinated peptide antibodies in Egyptian patients with chronic hepatitis C virus genotype IV infection.The Frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: A comparative study.The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis.Are anti-CCP antibodies in psoriatic arthritis patients a biomarker of erosive disease?Antibodies against cyclic citrullinated peptide (CCP) in inflammatory bowel disease patients with or without arthritic manifestations.Is osteoporosis an autoimmune mediated disorder?Dermoscopy of nail fold and elbow in the differential diagnosis of early psoriatic arthritis sine psoriasis and early rheumatoid arthritis.Consensus on the management of patients with psoriatic arthritis in a dermatology setting.Local bone loss in patients with anti-citrullinated peptide antibody and arthralgia, evaluated with high-resolution peripheral quantitative computed tomography.

P2860

Q24675281-6F1F9E3D-A1FB-4E41-8E8E-1E41393F68F1 Q27001098-4EEEFF69-8AB1-4215-B8C3-9AC3D9FAFC87 Q33419722-453659D7-050C-4A4F-A857-1D8F12B8828F Q33839099-5607D753-CE9E-4DD9-90CB-955BEC0B6671 Q33893385-4CF8E89C-AAA2-41F0-A692-722624924773 Q34451163-CCFD47A4-57AB-46EF-BAAE-5A53A10C1303 Q35309739-4760314A-275F-4AE1-A4BB-3A1F7302F5E9 Q35636880-8AFFCF68-1B81-4738-90DC-D1D97E2B7F0D Q35637484-AAB267E0-2416-4814-BE8B-2C056B10B11A Q35731234-C3CA24ED-8D7C-44D5-A5A9-08F3129FB8E5 Q35760091-C1FBFCE4-002B-4F61-88B9-15AF0E3FBBA6 Q35953359-0F5C548B-CB29-4D05-B183-8A7C4F896FA2 Q36237213-7AF96879-927E-4A5C-8B59-B6D0C3AB2642 Q36245883-58174371-2B9D-4B04-A020-2CA7DAED2F26 Q37217463-3FFC8496-7CD8-4F01-B03A-7E241AD2F66A Q37277807-C464244F-28F6-477B-8432-4FC34150496F Q37280952-C625F443-75A8-49C6-B13A-7AFCE1EEAC76 Q38416536-523AF959-7328-4358-9286-6B0A70530243 Q38896045-3FB70137-2F7D-45BC-8B77-303D12F553BC Q41228105-E4708C62-A61B-4D08-BCEE-DE1B59DE551F Q43158822-E74CEDA9-35C6-4AD4-8994-11C5F803404C Q44490496-81D395EF-7040-44F5-8018-25AA3934593A Q44721298-B59FE021-6EF4-4093-B71F-2C5539DC8F7D Q47097021-B38F8150-DA3C-4A70-899C-292D7F4A8DF8 Q47784677-0CC9762D-FAF1-496F-9F3E-24531322A4A4 Q50002313-26083AE3-4F19-4DCE-92BD-BC1BE26A6EC6 Q54235382-C877ED47-7802-477A-A59A-255C17A43F8C

P2860

Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis

http://www.wikidata.org/entity/Q35555882

description

2005 nî lūn-bûn

@nan

2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis

@ast

Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis

@en

type

label

Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis

@ast

Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis

@en

prefLabel

Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis

@ast

Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis

@en

P1433

Q35555882-03BDD241-B685-4ED7-B0C0-D98182A10BD8

P1476

Q35555882-0BF435A8-5C7B-4376-9F5B-9E4C3F0898BD

P2093

Q35555882-15AE97A3-807F-4E02-A774-E7B71D0E6173

Q35555882-2194B841-27F0-4676-ACCB-07CAC9E7C153

Q35555882-286DE4B7-E6A5-41C2-BDD3-D640480655CB

Q35555882-2FEF40E3-FD45-485A-BDE8-8316FDC1B5FC

Q35555882-502ABDF1-412C-49FB-81D8-1A93A302D773

Q35555882-6CD4CBFF-4B73-4733-99EA-5B046C042CC3

Q35555882-77248370-3C19-4F2A-9DBB-3886D957DE17

Q35555882-85C4EE10-7D3C-42D6-B1F1-14CF70B30976

Q35555882-A97528D9-B05B-42E2-B4A9-ED48273BE6D8

Q35555882-AF8B3471-395B-4224-B494-AA1EBC80226C

P2860

Q35555882-015C4DE9-20E1-42A8-AA5F-0813279C93D8

Q35555882-1B5F5D20-E6B5-446D-B624-9ADF9521CEED

Q35555882-21421B58-937A-4DB4-A4AC-7D564F38CD28

Q35555882-2949C76C-DD6D-43E7-899E-781F78F19DEF

Q35555882-2DF09903-97AD-4A8F-9D00-67FD34FECE65

Q35555882-4E7F1C9B-89BB-472B-91D3-B8C00B7D5E94

Q35555882-74BD04B7-A747-47D7-A826-CD74434BF4E7

Q35555882-9B0F7CB2-6FB2-43FC-A070-E079D145D27C

Q35555882-A07AB0B0-41AF-48F3-937F-5ED31FF7C346

Q35555882-AE4E4665-B626-476B-8CBB-4C0936BA1721

P304

Q35555882-95771FE4-37D5-45E5-B429-AEC7AB6DFA1D

P31

Q35555882-C75B73DF-EE5F-45A4-AFC6-D1365AA6D124

P356

Q35555882-301C7983-BBF9-4D88-A906-C00037A821E0

P407

Q35555882-366DE71B-4D52-4FBA-B9BC-3BC9D5F35677

P433

Q35555882-5AACC499-347C-478F-B2F9-E5DA97A69361

P478

Q35555882-CBDA7C36-2CD4-466E-BF7B-728805AB92FC

P577

Q35555882-E097E365-B8B5-472B-A1CC-14A42D72D492

P5875

Q35555882-92916B7B-B8DB-4198-B7CC-768BD3F29AEA

P698

Q35555882-2A92CFF4-38BD-4507-B78B-15AA0F4638F0

P921

Q35555882-1DEFB42A-7284-4891-B548-6A292668119E

P932

Q35555882-7063B2F6-CB08-486A-A9B8-EC03AD235ECD

P356

ARD.2004.032177

P1433

Annals of the Rheumatic Diseases

P1476

Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis

@en

P2093

Baeten D

http://www.w3.org/2001/XMLSchema#string

De Keyser F

http://www.w3.org/2001/XMLSchema#string

De Rycke L

http://www.w3.org/2001/XMLSchema#string

Hoffman IE

http://www.w3.org/2001/XMLSchema#string

Kruithof E

http://www.w3.org/2001/XMLSchema#string

Mielants H

http://www.w3.org/2001/XMLSchema#string

Van den Berghe M

http://www.w3.org/2001/XMLSchema#string

Vander Cruyssen B

http://www.w3.org/2001/XMLSchema#string

Veys EM

http://www.w3.org/2001/XMLSchema#string

Zmierczak H

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-keratin antibodies in rheumatoid arthritis

A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis

Reporting of precision of estimates for diagnostic accuracy: a review

Psoriatic arthritis: a unified concept twenty years on.

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations

Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.

P304

1145-1149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2004.032177

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8036228

http://www.w3.org/2001/XMLSchema#string

P698

15695535

http://www.w3.org/2001/XMLSchema#string

P921

P932

1755603

http://www.w3.org/2001/XMLSchema#string